



## **Dynavax Appoints Jane Green Vice President, Corporate Communications**

BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced the appointment of Jane Green, Ph.D., as Vice President, Corporate Communications. Dr. Green will be responsible for the company's external and internal communications programs, including investor relations, public relations, media relations and communications strategy.

"Jane joins Dynavax at an important time in our company's development, as we advance our clinical programs in allergy, infectious and chronic inflammatory disease, and continue to demonstrate the broad therapeutic and commercial potential of our ISS technology," said Dino Dina, M.D., president and chief executive officer. "Jane's extensive experience in creating targeted and effective communications programs and in building alliances with key audiences, and her knowledge of the biotechnology and healthcare industries, will strengthen our ability to broaden understanding of our corporate strategy and highlight what we believe is our company's exciting near- and long-term investment potential."

Dr. Green joins Dynavax from Exelixis, Inc. where she developed and managed the company's communications strategy to support its transition from a technology to product-focused enterprise. Prior to Exelixis, she was senior director of corporate communications at Caliper Technologies, where she coordinated Caliper's initial public offering, built the company's investor, media and public relations programs and initiated its marketing communications strategy. Prior to joining Caliper, she directed corporate communications and investor relations for Isis Pharmaceuticals, and prior to that she held various positions with Rhone-Poulenc Rorer (now Sanofi Aventis) in international corporate communications and federal government relations. Dr. Green holds a B.A. in literature from the University of Pennsylvania and a Ph.D. in English literature from the State University of New York at Buffalo.

### **About Dynavax**

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three separate indications: a ragweed allergy program and a Hepatitis B vaccine program in late stage clinical development, and an asthma program that just completed a Phase II exploratory trial.

Dynavax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to plans to advance its clinical programs and demonstrate the potential of its ISS technology. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Dynavax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Dynavax's business including, without limitation, risks relating to: the progress and timing of its clinical trials; difficulties or delays in developing, testing, obtaining regulatory approval of, producing and marketing its products; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to maintain effective financial planning and internal controls; and other risks detailed in the "Risk Factors" section of Dynavax's Annual Report on Form 10-K filed on June 30, 2004, and in the section titled "Additional Factors That May Affect Future Results" within Dynavax's quarterly report on Form 10-Q filed on August 9, 2004. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Dynavax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

SOURCE Dynavax Technologies Corporation

09/27/2004

CONTACT: Jane Green, Vice President, Corporate Communications of Dynavax Technologies Corporation, 510-665-4630, or [jgreen@dvax.com](mailto:jgreen@dvax.com)

Web site: <http://www.dynavax.com>  
(DVAX)

09/27/2004 06:00 EDT <http://www.prnewswire.com>